Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Health Care Select Sector SPDR / Technical Analysis

<ul>
<li>As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024.</li>
<li>Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume (XLK, SMH, IGV, ARKK, IPO, BITQ)</li>
<li>Other Sectors are picking up the slack, namely Health Care (XLV), Staples (XLP), Utilities (XLU), Energy (XLE), Financials (XLF), and Real Estate (XLRE). Shift exposure toward value and defensives</li>
</ul>


As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024.
Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume (XLK, SMH, IGV, ARKK, IPO, BITQ)
Other Sectors are picking up the slack, namely Health Care (XLV), Staples (XLP), Utilities (XLU), Energy (XLE), Financials (XLF), and Real Estate (XLRE). Shift exposure toward value and defensives


Upgrading Staples and Health Care to Market Weight; Shift to Value; Failed Breakouts for ARKK, IPO

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall Street.</li><li>The company achieved decent results in developed markets, with a full European version driven by critical brands and generics.</li><li>The company expects mid-single-digit growth in this segment, primarily driven by the brand category.</li></ul>

Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall Street.The company achieved decent results in developed markets, with a full European version driven by critical brands and generics.The company expects mid-single-digit growth in this segment, primarily driven by the brand category.

Viatris Inc.: Emerging Market Growth Makes Up Disappointing Performance? – Key Drivers

<ul><li>Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat.</li><li>They dealt with intense competition for important products like Wixela and the loss of exclusivity for Miacalcin and Perforomist.</li><li>In addition, they acquired Oyster Point Pharma and Famy Life Sciences in January to create their new Viatris Eye Care division.</li></ul>

Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat.They dealt with intense competition for important products like Wixela and the loss of exclusivity for Miacalcin and Perforomist.In addition, they acquired Oyster Point Pharma and Famy Life Sciences in January to create their new Viatris Eye Care division.

Credit

<ul><li>Viatris is a well-known global healthcare major with operations spread across North America, Europe, China, and other markets.</li><li>The company’s financial performance has been in recovery mode and has been impacted by numerous industry headwinds, especially inflationary pressures.</li><li>It had an interesting set of developments which included a strategic agreement to sell off their biosimilars business to Biocon Biologics.</li></ul>

Viatris is a well-known global healthcare major with operations spread across North America, Europe, China, and other markets.The company’s financial performance has been in recovery mode and has been impacted by numerous industry headwinds, especially inflationary pressures.It had an interesting set of developments which included a strategic agreement to sell off their biosimilars business to Biocon Biologics.

Viatris Inc: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>This is our first report on global healthcare giant, Viatris.</li><li>The company had an interesting set of developments which included a strategic agreement to sell off their biosimilars business to Biocon Biologics.</li><li>Due to the Famy Life Sciences acquisition, five more front-of-the-eye programs in diverse indications that are in Phase III or are ready for Phase III will be added.</li></ul>

This is our first report on global healthcare giant, Viatris.The company had an interesting set of developments which included a strategic agreement to sell off their biosimilars business to Biocon Biologics.Due to the Famy Life Sciences acquisition, five more front-of-the-eye programs in diverse indications that are in Phase III or are ready for Phase III will be added.

Viatris Inc: Initiation of Coverage – Recent Acquisitions & Other Drivers

United States

Viatris Inc. operates as a pharmaceutical company. The Company produces medicines for patients across broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Viatris serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viatris (VTRS US)

Upgrading Staples and Health Care to Market Weight; Shift to Value; Failed Breakouts for ARKK, IPO

Shifting exposure toward value and defensives. Upgrading Consumer Staples $XLP and Health Care $XLV to market weight. $ARKK and $IPO with bearish...

Vermilion Research

Viatris Inc.: Emerging Market Growth Makes Up Disappointing Performance? – Key Drivers

Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall...

Baptista Research

Viatris Inc.: Major Drivers

Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat. They dealt...

Baptista Research

Viatris Inc: Detailed Credit Analysis & Financial Strength Evaluation Report

Viatris is a well-known global healthcare major with operations spread across North America, Europe, China, and other markets. The company’s...

Baptista Research

Viatris Inc: Initiation of Coverage – Recent Acquisitions & Other Drivers

This is our first report on global healthcare giant, Viatris. The company had an interesting set of developments which included a strategic...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)